Actavis Group (ACT), the international generic pharmaceutical company, today announces that it has acquired the Czech generic pharmaceutical company Pharma Avalanche. Financial details were not disclosed.

Headquartered in Prague, Pharma Avalanche was established in 2000 and currently employs 30 people. Its primary focus is on the marketing and sale of generic pharmaceuticals on the Czech and Slovak Republic markets.

The acquisition is not expected to have any material effect on Actavis’ financial results.

Commenting on the acquisition, Sigurdur Oli Olafsson Chief Executive of Corporate Development said: "This acquisition is in line with our strategy to extend Actavis’ presence in central Europe. It provides us with a direct sales and marketing presence on the Czech and Slovak Republic markets. This also gives us a good platform from which to register and launch Actavis products in these markets."